Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Bio-Rad Laboratories, Inc. Class B (BIO.B) Stock Price & Analysis

BIO.B Stock Chart & Stats

382.23-4.45(-1.15%)
At close: 4:00 PM EDT
$340$360$3803 Aug20 Aug14 Oct27 Oct
Day’s Range
$368.66 - $395.80
52-Week Range
$238.69 - $426.54
Previous Close
$386.69
Volume
N/A
Average Volume (3M)
15
Market Cap
$10.00B
Enterprise Value
$7.96B
Total Cash (Recent Filing)
$1.62B
Total Debt (Recent Filing)
$1.20B
Price to Earnings (P/E)
44.7
Beta
1.01
Next Earnings
Nov 04, 2026 (Est.)
EPS Estimate
2.23
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet Strength

Conservative leverage and a large equity cushion give Bio-Rad financial resilience while preserving flexibility for investment, acquisitions, restructuring, and shareholder returns. Lower total debt versus 2025 further reduces balance-sheet pressure as the company manages uneven operating performance.

Clinical Diagnostics Recovery

Clinical Diagnostics returning to currency-neutral growth provides a durable counterweight to weakness in Life Science. Strength in quality controls and blood typing supports recurring laboratory workflows and indicates that Bio-Rad retains meaningful relevance across essential clinical testing markets.

Digital PCR Product Momentum

Strong digital PCR instrument growth, competitive wins, and conversions from qPCR support a favorable product-cycle opportunity. Bio-Rad's assay menu, installed base, and scientific publications can reinforce adoption and create a foundation for longer-term consumables pull-through.

Bears Say

Weak Revenue Outlook

The full-year outlook indicates that Bio-Rad is still operating in a weak demand environment, particularly in Life Science. Near-flat to declining revenue limits operating leverage, makes growth investment harder to absorb, and delays a clearer recovery in the company's earnings base.

Margin And Cost Pressure

Lower operating margin alongside higher SG&A shows that cost growth is currently outpacing revenue performance. If this persists, Bio-Rad may have less capacity to convert its solid gross profitability into earnings and may need sustained efficiency actions to restore profitability.

Restructuring Execution Burden

The restructuring may improve efficiency over time, but its long implementation period and substantial upfront cost create near-term execution and earnings burdens. Minimal 2026 savings mean the company must absorb transition costs before the targeted benefits and margin expansion become meaningful.

BIO.B FAQ

What was Bio-Rad Laboratories, Inc. Class B’s price range in the past 12 months?
Bio-Rad Laboratories, Inc. Class B lowest stock price was $238.69 and its highest was $426.54 in the past 12 months.
What is Bio-Rad Laboratories, Inc. Class B’s market cap?
Bio-Rad Laboratories, Inc. Class B’s market cap is $10.00B.
When is Bio-Rad Laboratories, Inc. Class B’s upcoming earnings report date?
Bio-Rad Laboratories, Inc. Class B’s next earnings report is estimated for Nov 04, 2026 (not yet confirmed), which is in 2 days.
How were Bio-Rad Laboratories, Inc. Class B’s earnings last quarter?
Bio-Rad Laboratories, Inc. Class B released its earnings results on Aug 04, 2026. The company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.782 by $0.838.
Is Bio-Rad Laboratories, Inc. Class B overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Bio-Rad Laboratories, Inc. Class B pay dividends?
Bio-Rad Laboratories, Inc. Class B does not currently pay dividends.
What is Bio-Rad Laboratories, Inc. Class B’s EPS estimate?
Bio-Rad Laboratories, Inc. Class B’s EPS estimate is 2.23.
How many shares outstanding does Bio-Rad Laboratories, Inc. Class B have?
Bio-Rad Laboratories, Inc. Class B has 5,061,038 shares outstanding.
What happened to Bio-Rad Laboratories, Inc. Class B’s price movement after its last earnings report?
Bio-Rad Laboratories, Inc. Class B reported an EPS of $2.62 in its last earnings report, beating expectations of $1.782. Following the earnings report the stock price went up 5.93%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories, Inc. Class B?
Currently, no hedge funds are holding shares in BIO.B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology